Why Taysha’s Rett syndrome data could become a major gene therapy test case
Find out how Taysha’s TSHA-102 Rett syndrome update could shape gene therapy development, BLA planning and future disease-modifying care.
Pharma & Biotech
Pharma & Biotech
Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.
Medical Devices & Diagnostics
PanopticAI adds FDA-cleared respiratory rate to its smartphone vital-signs platform
FDA clearance for contactless respiratory-rate measurement expands PanopticAI’s regulated digital-health platform, but restricted use, cloud dependence and uncertain reimbursement remain major commercial tests.
Pharma & Biotech
Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test
Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.
Pharma & Biotech
Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny
Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.
Pharma & Biotech
Does sonelokimab finally justify MoonLake’s best-in-class hidradenitis suppurativa claim?
Sonelokimab delivered deeper one-year hidradenitis suppurativa responses, but MoonLake must convert cross-trial advantages into regulatory approval and commercial differentiation.
Medical Devices & Diagnostics
Can IceCure Medical turn 70% ProSense installation growth into durable breast cancer revenue?
IceCure Medical’s FDA-authorised breast cancer cryoablation platform is gaining United States installations, but narrow eligibility, postmarket evidence requirements and heavy dilution complicate the small-cap investment case.
Pharma & Biotech
Voro and Alloy target safer masked T-cell engager therapies in oncology
Find out how Voro Therapeutics and Alloy Therapeutics aim to advance safer masked T-cell engager cancer therapies.
Pharma & Biotech
Can 101 Therapeutics’ macrophage-targeting approach change the race for a Bundibugyo Ebola treatment?
101 Therapeutics has released new data on 101-PGC-005 for Bundibugyo Ebola disease. Discover what it could mean for outbreak response and drug development.
Medical Devices & Diagnostics
Why Premier Biotech’s NexScreen and TransMed acquisitions could reshape rapid drug testing
Discover how Premier Biotech’s NexScreen and TransMed acquisitions expand point-of-care testing, e-commerce and global diagnostics reach.